Sebetralstat is a small molecule plasma kallikrein inhibitor approved for the on-demand treatment of acute attacks of hereditary angioedema. By preventing the excessive bradykinin production associated… Read more
Sebetralstat is a small molecule plasma kallikrein inhibitor approved for the on-demand treatment of acute attacks of hereditary angioedema. By preventing the excessive bradykinin production associated with this condition, the drug helps manage sudden swelling episodes. This category provides essential materials for pharmaceutical research and development, including the Sebetralstat active pharmaceutical ingredient reference standard. Analytical chemists and quality control laboratories utilize these related compounds, including synthetic impurities, potential degradation products, and stable isotope-labelled standards, to support rigorous method validation and impurity profiling. Access to high-quality reference materials is critical for ensuring the accuracy of quantitative analysis and identifying unknown peaks in chromatographic testing during the lifecycle management of the drug product. These compounds support the precise characterization required to maintain compliance with regulatory standards for therapeutic safety and consistency.